January 2026 Research Update

This month, the clearest new human evidence focused on where idursulfase infusions happen rather than whether the drug works. In a large real-world registry, home infusions looked broadly as safe and tolerable as in-clinic infusions, and people missed fewer infusions during the home period. This adds reassurance that home delivery can be comparable to clinic delivery for many patients when programs are set up to support it. [1]

When the same patients were compared across their in-clinic and home periods, infusion-related reactions were similar, and most reactions were mild. The overall rate of reported adverse events was also similar or lower during the home period compared with the in-clinic period. These findings describe what was observed in routine care, and they help put safety concerns about the infusion setting into a more practical, real-world context. [1]

The registry analysis also reported fewer missed infusions during home therapy than during the in-clinic period for the same patients. Since idursulfase is given on a regular schedule, fewer missed infusions may reflect easier logistics for families. The study also reported deaths over time and did not consider any deaths to be treatment-related, but this kind of comparison in registry data cannot explain why differences happen. [1]

For patients and caregivers, this mainly speaks to infusion burden and day-to-day feasibility, not to changing the medical role of idursulfase. The evidence comes from a large registry, so it may matter now for understanding what has been seen in routine care, but it does not prove that the infusion setting itself causes better or worse outcomes. What remains uncertain is which patients are best suited for home infusions and how differences in support, training, and reporting may affect reaction and adverse-event rates. [1]

This month added a clearer picture of what counts as a meaningful change for young children with neuronopathic Hunter syndrome when researchers use child development testing. Caregivers described that even small gains over a year could feel meaningful, and they connected specific areas of development to real daily activities. This helps research studies interpret whether a measured change is likely to matter to families, rather than treating all score changes as equally important. [2]

In caregiver interviews using hypothetical examples, many caregivers said that a 2-month increase in age-equivalent scores over 1 year would be meaningful across tested areas. Smaller 1-month increases were also often considered meaningful, especially for expressive communication and fine motor skills. The same caregivers described how items related to thinking skills, expressive language, and fine motor tasks show up in routines like communication, participation, and independence. [2]

For families, this work mainly affects how research results may be communicated and understood, especially in studies that track development over time. It may matter more in the future as trials and observational studies try to show benefits that are small but still important in everyday life, because it gives a patient-centered way to interpret test changes. What remains uncertain is how well these interview-based thresholds apply across all children with neuronopathic MPS II, since the group was small and children can progress very differently. [2]

This month, laboratory studies pushed forward two building blocks for future therapies: how to raise IDS enzyme levels in the body, and how to model Hunter-like problems in simpler organisms. In mice, a gene-editing approach produced high IDS activity and improvements in visible disease signs, while in fruit flies, lowering IDS in the brain shortened lifespan in males. Together, these studies strengthen the research toolkit, but they do not tell us yet what will happen in people. [3] [4]

In a small mouse study, a CRISPR/Cas9-based approach delivered by AAV was used to insert a human IDS gene sequence into the liver. Treated mice showed markedly higher IDS production in the liver and higher IDS activity in the blood, and they also showed improvements in movement and skeletal development compared with untreated or control-treated MPS II mice. The researchers reported limited off-target findings in their sequencing checks and no observed adverse effects in the treated mice during the study period. [3]

In a fruit-fly model meant to mimic lysosomal storage disorders, reducing IDS in the nervous system shortened lifespan in male flies, while females were largely spared in this specific model. Changing IDS in the midgut did not show the same lifespan effect. This kind of work helps researchers test ideas quickly, but a fly model cannot capture the full body and brain complexity of Hunter syndrome. [4]

For patients and caregivers, these studies are mainly early research that may matter later if similar results can be reproduced and translated into human studies. The mouse gene-editing results help clarify that long-lasting increases in IDS activity and improvements in disease signs are possible in an animal model, but the study was very small and long-term human safety is unknown. The fly work helps clarify that IDS loss in the nervous system can drive movement problems in a simple model, but it cannot predict symptom change, timing, or treatment effects in children or adults with MPS II. [3] [4]